DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2221375/ligand-pharmaceuticals-lgnd-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2221375 Feb 05, 2024 - In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $74.72, denoting a +0.24% change from the preceding trading day. 0

https://www.zacks.com/stock/news/2242754/ligand-lgnd-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2242754 Mar 19, 2024 - According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.zacks.com/stock/news/2250019/ema-accepts-rocket-rckt-gene-therapy-filing-for-fanconi-anemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250019 Apr 03, 2024 - The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow. 0

https://www.zacks.com/stock/news/2249959/vanda-vnda-up-on-fda-nod-for-fanapt-in-bipolar-i-disorder?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249959 Apr 03, 2024 - Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%. 0

https://www.zacks.com/stock/news/2250719/amarin-amrn-up-7-on-intellectual-property-wins-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250719 Apr 04, 2024 - Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties. 0

https://www.zacks.com/stock/news/2250421/wall-street-analysts-think-ligand-lgnd-is-a-good-investment-is-it?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2250421 Apr 04, 2024 - According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.zacks.com/stock/news/2251363/candel-cadl-up-on-upbeat-data-from-pancreatic-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251363 Apr 05, 2024 - Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises. 0

https://www.zacks.com/stock/news/2252667/is-it-a-good-idea-to-invest-in-adma-biologics-adma-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252667 Apr 09, 2024 - Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now. 0

https://www.zacks.com/stock/news/2253377/lisata-s-lsta-lsta1-gets-fda-orphan-drug-tag-for-osteosarcoma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253377 Apr 10, 2024 - The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises. 0

https://www.zacks.com/stock/news/2254638/astrazeneca-s-azn-fasenra-gets-fda-nod-for-asthma-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254638 Apr 12, 2024 - The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years. 0